-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Pyxis Oncology, Inc. (NASDAQ:PYXS) Short Interest Up 286.1% in November
Pyxis Oncology, Inc. (NASDAQ:PYXS) Short Interest Up 286.1% in November
Pyxis Oncology, Inc. (NASDAQ:PYXS – Get Rating) saw a large growth in short interest during the month of November. As of November 15th, there was short interest totalling 160,600 shares, a growth of 286.1% from the October 31st total of 41,600 shares. Approximately 0.8% of the company's stock are short sold. Based on an average daily volume of 78,100 shares, the days-to-cover ratio is currently 2.1 days.
Pyxis Oncology Stock Performance
PYXS stock traded down $0.07 during trading on Tuesday, hitting $1.38. 2,489 shares of the stock traded hands, compared to its average volume of 123,070. Pyxis Oncology has a 1 year low of $1.34 and a 1 year high of $13.09. The firm's 50 day moving average is $1.69 and its two-hundred day moving average is $2.27.
Get Pyxis Oncology alerts:Pyxis Oncology (NASDAQ:PYXS – Get Rating) last announced its quarterly earnings data on Tuesday, November 1st. The company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.09). Sell-side analysts expect that Pyxis Oncology will post -3.64 EPS for the current fiscal year.
Institutional Trading of Pyxis Oncology
Institutional investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. purchased a new stake in Pyxis Oncology during the 2nd quarter valued at about $31,000. Tower Research Capital LLC TRC boosted its holdings in shares of Pyxis Oncology by 414.2% during the 3rd quarter. Tower Research Capital LLC TRC now owns 15,736 shares of the company's stock valued at $31,000 after acquiring an additional 12,676 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Pyxis Oncology by 69.0% during the 1st quarter. Bank of New York Mellon Corp now owns 32,589 shares of the company's stock valued at $132,000 after acquiring an additional 13,305 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in shares of Pyxis Oncology during the 2nd quarter valued at about $179,000. Finally, Millennium Management LLC purchased a new stake in shares of Pyxis Oncology during the 2nd quarter valued at about $340,000. 71.59% of the stock is owned by hedge funds and other institutional investors.Pyxis Oncology Company Profile
(Get Rating)
Pyxis Oncology, Inc, a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors.
Featured Stories
- Get a free copy of the StockNews.com research report on Pyxis Oncology (PYXS)
- Three Reasons It's Time To Get Bullish On Organigram
- Opportunity Strikes! Hibbett, Inc Falls Flat On Strong Results
- Why Investors Are Eating Up Restaurant Brands International
- Zoom Video Continues to Work Through Normalization
- What an Inverted Yield Curve Means for Investors
Receive News & Ratings for Pyxis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
Pyxis Oncology, Inc. (NASDAQ:PYXS – Get Rating) saw a large growth in short interest during the month of November. As of November 15th, there was short interest totalling 160,600 shares, a growth of 286.1% from the October 31st total of 41,600 shares. Approximately 0.8% of the company's stock are short sold. Based on an average daily volume of 78,100 shares, the days-to-cover ratio is currently 2.1 days.
Pyxis Oncology, Inc.（纳斯达克股票代码：PYXS — Get Rating）在11月份的空头利率大幅增长。截至11月15日，空头利率共计160,600股，较10月31日的41,600股总额增长了286.1％。该公司约有0.8％的股票被卖空。根据78,100股的平均每日成交量，目前天数与覆盖率为2.1天。
Pyxis Oncology Stock Performance
Pyxis 肿瘤学股票表现
PYXS stock traded down $0.07 during trading on Tuesday, hitting $1.38. 2,489 shares of the stock traded hands, compared to its average volume of 123,070. Pyxis Oncology has a 1 year low of $1.34 and a 1 year high of $13.09. The firm's 50 day moving average is $1.69 and its two-hundred day moving average is $2.27.
PYXS股票在周二的交易中下跌0.07美元，至1.38美元。该股交易中有2489股，而平均交易量为123,070股。Pyxis Oncology创下1年低点1.34美元，1年高点13.09美元。该公司的50天移动平均线为1.69美元，其200天移动平均线为2.27美元。
Pyxis Oncology (NASDAQ:PYXS – Get Rating) last announced its quarterly earnings data on Tuesday, November 1st. The company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.09). Sell-side analysts expect that Pyxis Oncology will post -3.64 EPS for the current fiscal year.
Pyxis Oncology（纳斯达克股票代码：PYXS — Get Rating）上次公布季度收益数据是在11月1日星期二。该公司公布了本季度每股收益（0.85美元），比市场普遍预期的（0.76美元）低了（0.09美元）。卖方分析师预计，Pyxis Oncology将在本财年公布每股收益为-3.64。
Institutional Trading of Pyxis Oncology
Pyxis Oncology 的机构交易
Pyxis Oncology Company Profile
Pyxis 肿瘤学公司简介
(Get Rating)
（获取评分）
Pyxis Oncology, Inc, a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors.
Pyxis Oncology, Inc是一家临床前阶段的生物制药公司，从事癌症治疗疗法的开发。其免疫肿瘤学候选产品包括 PYX-106，一种用于治疗甲状腺癌、头颈部鳞状细胞癌、非小细胞肺癌 (NSCLC) 和其他实体瘤的在研全人免疫球蛋白 G1 同型 siglec-15 靶向抗体；以及 PYX-102，一种用于治疗实体瘤的在研免疫疗法。
Featured Stories
精选故事
- Get a free copy of the StockNews.com research report on Pyxis Oncology (PYXS)
- Three Reasons It's Time To Get Bullish On Organigram
- Opportunity Strikes! Hibbett, Inc Falls Flat On Strong Results
- Why Investors Are Eating Up Restaurant Brands International
- Zoom Video Continues to Work Through Normalization
- What an Inverted Yield Curve Means for Investors
- 免费获取 StockNews.com 关于 Pyxis Oncology (PYXS) 的研究报告
- 是时候看好 Organigram 的三个原因了
- 机会来袭！Hibbett, Inc. 因业绩强劲而持平
- 为什么投资者正在吞噬国际餐厅品牌
- Zoom 视频通过标准化继续发挥作用
- 收益率曲线倒置对投资者意味着什么
Receive News & Ratings for Pyxis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Pyxis Oncology Daily 的新闻和 -在下面输入您的电子邮件地址，通过Marketbeat.com的免费每日电子邮件时事通讯接收Pyxis Oncology及相关公司的最新新闻和分析师评级的简明每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧